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SUMMARY – Fabry disease is a rare X-linked inherited lysosomal storage disease aff ecting mul-
tiple organ systems, presenting in the central nervous system (CNS) as white matter lesions with 
underlying cerebral vasculopathy and autoinfl ammatory changes of the choroid plexus and leptomen-
inges. We present a young female patient (age 36 years) admitted to our department due to visual loss 
on the left eye. Magnetic resonance imaging (MRI) showed demyelinating lesions in the frontal and 
parietal lobe, periventricularly, in mesencephalon and right cerebellar hemisphere, and left optic neu-
ritis; MR angiography was normal. Her medical history revealed renal dysfunction, hypothyroidism, 
and miscarriage in the 6th month of pregnancy due to eclampsia and Fabry disease in the family 
(mother). Cerebrospinal fl uid analysis showed mild pleocytosis, normal blood brain barrier function 
and oligoclonal bands type 3. Visual evoked potentials showed prechiasmal dysfunction of the left 
optic nerve. Genetical testing for Fabry disease was positive (two heterozygous mutations), with de-
creased alpha galactosidase activity values and increased Lyso GB3 values. Th e patient received corti-
costeroid therapy (methylprednisolone) 1 g for 5 days, which led to regression of visual disturbances 
on the left eye. After this acute treatment, there was a question of defi nitive diagnosis and further 
treatment of the underlying cause. Considering renal dysfunction, miscarriage, arterial hypertension, 
positive genetic and biochemical testing for Fabry disease, as well as MRI fi ndings showing lesions in 
posterior circulation, we concluded that the patient probably had Fabry disease with autoinfl amma-
tory changes in the CNS and should be treated with enzyme replacement therapy. Still, there was a 
question of optic neuritis on the left eye and positive oligoclonal bands favoring the diagnosis of 
multiple sclerosis. Th erefore, further clinical and neuroradiological follow up was needed to distin-
guish multiple sclerosis and Fabry disease in this patient.
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Introduction
Fabry disease is an X-linked inherited lysosomal 
storage disease caused by mutations (or alterations) in 
the a-Gal A (GLA) gene that result in insuffi  cient ac-
tivity of the a-Gal A enzyme. Lysosomes are primary 
digestive units within cells, therefore they are enriched 
with enzymes which break down or digest particular 
compounds and intracellular structures. Th e function 
of the GLA enzymes is to break down globotriaosyl-
ceramide (GL-3 or Gb3), lyso-GL-3/Gb3 and related 
glycolipids by removing terminal galactose sugar from 
the end of these glycolipid molecules. Th e enzyme de-
fi ciency causes continuous build-up of GL-3/Gb3 and 
related glycolipids in the body cells, resulting in cell 
abnormalities and organ dysfunction1-3. Due to X-
linked inheritance pattern, males are typically more 
severely aff ected than females. Females have a more 
variable course and may be asymptomatic or as severe-
ly aff ected as males due to so-called lyonization, i.e. 
females have two copies of the X chromosome, one of 
which is inactivated randomly, thus they have no phe-
notypic expression. Th erefore, there is always lower 
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GLA enzyme level in plasma, while in females GLA 
enzyme activity levels depend not only on GLA muta-
tions of the X chromosome, but also on the lyonization 
eff ect4,5.
Fabry disease is estimated to aff ect 1 in 40,000 to 
60,000 males. Th is disorder also occurs in females, al-
though the prevalence is unknown. Milder, late-onset 
forms of the disorder are probably more common than 
the classic, severe form. Th e average age at diagnosis is 
approximately 30 years. Delayed diagnosis may be due 
to the rarity of the disease and/or the nonspecifi c na-
ture of its early symptoms6,7.
Th ere are two major disease phenotypes, i.e. type 1 
‘classic’ and type 1 ‘later-onset’ subtypes. Th e signs and 
symptoms of classic phenotype typically begin in 
childhood or adolescence. Symptoms increase with age 
due to the progressive glycolipid accumulation in the 
vascular system, kidneys and heart leading to kidney 
failure, heart disease or strokes. Early and progressive 
clinical symptoms include acroparesthesias, anhidro-
sis or hypohidrosis, angiokeratomas, gastrointestinal 
problems, and corneal dystrophy. Additional symp-
toms include chronic fatigue, dizziness, headache, gen-
eralized weakness, nausea, vomiting, delayed puberty, 
lack of or sparse hair growth, and rarely malformation 
of the joints of the fi ngers.
Involvement of the central nervous system (CNS) 
in Fabry disease patients is mainly due to cerebral vas-
culopathy aff ecting both small and large cerebral ves-
sels. Macroangiopathy usually leads to ischemic stroke, 
while microangiopathy is usually the cause of progres-
sive white matter lesions confi rmed by magnetic reso-
nance imaging (MRI) in about 80% of Fabry disease 
patients (both genders). Because of its clinical presen-
tation, as well as previously mentioned MRI fi ndings, 
Fabry disease takes an important place in the diff eren-
tial diagnosis of multiple sclerosis (MS). Clinicians 
should be extremely careful in establishing diagnosis 
in patients with Fabry disease because intermittent 
Fabry symptoms can be misleading and patient can 
fulfi ll Mc Donald criteria for MS, as well as aberra-
tions in cerebrospinal fl uid fi nding suggesting MS8,9.
Case Report
We present a young female patient (age 36 years) 
admitted to our department due to visual loss on the 
left eye. MRI showed demyelinating lesions in the 
frontal and parietal lobe, periventricularly, in mesen-
cephalon and right cerebelar hemisphere, and left op-
tic neuritis; MR angiography was normal. Th e patient’s 
history revealed renal dysfunction, hypothyroidism, 
and miscarriage in the 6th month of pregnancy due to 
eclampsia and genetically confi rmed Fabry disease in 
the family (mother and one sister). Cerebrospinal fl uid 
analysis showed mild pleocytosis, normal blood brain 
barrier function, and oligoclonal bands type 3. Visual 
evoked potentials showed prechiasmal dysfunction of 
the left optic nerve. Genetic testing for Fabry disease 
was positive (two heterozygous mutations), with de-
creased alpha galactosidase activity values and in-
creased Lyso GB3 values. Neurological examination 
showed loss of visual acuity on the left eye, without any 
other neurological signs and symptoms.
Th e patient received corticosteroid therapy (meth-
ylprednisolone) 1 g for 5 days, which led to regression 
of visual disturbances on the left eye.
After this acute treatment, there was a question of 
defi nitive diagnosis and further treatment of the un-
derlying cause. Considering renal dysfunction, miscar-
riage, arterial hypertension, positive genetic and bio-
chemical testing for Fabry disease, as well as MRI 
fi ndings showing lesions in posterior circulation (Figs. 
1-4), we concluded that the patient probably had Fab-
ry disease with microangiopathy complications (auto-
infl ammatory vasculopathy) of the brain white matter, 
which required treatment with enzyme replacement 
therapy. Still, there was a question of optic neuritis of 
the left eye and positive oligoclonal bands favoring the 
diagnosis of MS. Th erefore, further clinical and neuro-
radiological follow up was needed to distinguish MS 
and Fabry disease in this patient.
Discussion
Fabry disease aff ects young people and can have 
monosymptomatic courses, which only involve CNS 
without any medical history of other classic Fabry 
symptoms such as angiokeratoma, cornea veriticillata, 
or heart and kidney disease. MS is one of the most 
common neurologic diseases in young population of 
Western countries. Diff erential diagnosis of MS re-
quires detailed workup to exclude any other infl amma-
tory or non-infl ammatory brain white matter diseases 
mimicking clinical and/or MRI features of MS. Over-
presentation or intermittent presentation of cerebellar 
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and/or brain stem symptoms (ataxia, gait disturbances, 
double vision, vertigo, posterior vascular territory 
symptoms) in combination with sensory defi cits due 
to small fi ber lesions, as well as white matter lesions on 
MRI, can mislead clinicians in establishing diagnosis 
of MS according to temporal and space dissemination. 
Usually MRI of the cervical spinal cord is not per-
formed in Fabry patients, and lesions at these locations 
are probably underestimated. In most cases, there are 
no white matter lesions in the spinal cord in Fabry pa-
tients, which can be one of the distinguishing param-
eters9. Changes in the cerebrospinal fl uid are also pres-
ent in Fabry patients and are defi ned as ‘aseptic men-
ingitis’ or chronic meningitis with mild to moderate 
pleocytosis (76 cells/μL) and slightly elevated total 
protein levels (up to 800 mg/L) suggesting disturbed 
blood brain barrier function, mostly with lympho-
monocytic response. Results of the postmortem stud-
ies showed high accumulation of ceramide trihexo-
sides in the choroid plexus and leptomeninges in one 
Fabry patient. Th ese fi ndings suggest an aseptic in-
fl ammatory process triggered by the stored lipids act-
ing as foreign body stimulus. Oligoclonal bands can 
also be positive in cerebrospinal fl uid of Fabry patients, 
they have high sensitivity in MS patients, but they also 
are highly unspecifi c and can occur even after unspe-
Fig. 1. Horizontal T2 MRI section: 
multiple demyelinating lesions.
Fig. 2. Horizontal T2 MRI section: 
multiple demyelinating lesions.
Fig. 3. Sagittal T1 MRI section: 
multiple demyelinating lesions.
Fig. 4. Sagittal T1 MRI section: 
multiple demyelinating lesions.
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cifi c infections. Establishing diagnosis of Fabry disease 
is challenging, especially in patients without non-neu-
rologic manifestations of Fabry disease. According to 
previous studies, Fabry diagnosis should be considered 
in female patients with asymmetric, confl uent white 
matter lesions on MRI without or with very mild cor-
pus callosum T1 hyperintensities and/or lack of gado-
linium enhancement and/or normal spinal MRI, ec-
tatic vertebrobasilar arteries, and/or negative oligoclo-
nal bands, signifi cant proteinuria or unexplained left 
ventricular hyperthrophy, and a relative that died at a 
young age from unspecifi ed renal, cardiac or cerebro-
vascular disease (X-linked)10,11.
Establishing an accurate diagnosis in the early 
stages of both Fabry disease and MS is of great impor-
tance in planning long term treatment which will cure 
symptoms and underlying condition, while preventing 
organ damage and disabilities. In Fabry patients, en-
zyme replacement therapy has shown good results in 
disease control. In MS, there are numerous possibili-
ties of acute treatment, as well as immunomodulatory 
therapy. Th erefore, an accurate and timely diagnosis (in 
early stages of the disease if possible) is the best prog-
nostic factor for successful disease control8.
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Sažetak
MULTIPLA SKLEROZA ILI FABRIJEVA BOLEST – ZA I PROTIV
I. Zavoreo, M. J. Jurašić, M. Lisak, A. Jadrijević Tomas i V. Bašić Kes
Fabryjeva bolest je rijetka X vezana lizosomska bolest nakupljanja koja zahvaća više organskih sustava u organizmu, a u 
središnjem živčanom sustavu (SŽS) se prezentira kao lezije bijele tvari koje su posljedica vaskulopatije i autoimunih procesa 
na razini koroidnog pleksusa. U radu se prikazuje slučaj mlade žene (36 godina) koja je primljena na našu Kliniku zbog 
 poremećaja vida na lijevom oku. Nalaz magnetske rezonance (MR) mozga je pokazao demijelinizacijske lezije u frontalnom 
i parijetalnom režnju, periventrikularno, u mezencefalonu, desnoj hemisferi malog mozga te optički neuritis lijevo. Nalaz MR 
angiografi je mozga je bio uredan. U osobnoj anamnezi se doznaje da se bolesnica liječila zbog bubrežne insufi cijencije, hipo-
tireoze te da je u 6. mjesecu trudnoće imala spontani pobačaj uslijed eklampsije. U obiteljskoj anamnezi se doznaje da majka 
boluje od Fabryjeve bolesti. U analizi cerebrospinalnog likvora nađe se blaga pleocitoza, uredna funkcija krvnomoždane 
 barijere te sinteza IgG unutar SŽS-a, oligoklonske vrpce tip 3. Vidni evocirani potencijali pokazali su disfunkciju prekjaz-
malno lijevo. Genetsko testiranje na Fabryjevu bolest pokazalo je pozitivan nalaz, 2 heterozigotne mutacije, smanjenu aktiv-
nost alfa galaktosidaze te povišene vrijednosti Lyso GB3. Bolesnica je primila pulsnu kortikosteroidnu terapiju (metilpred-
nisolon 1 g) kroz 5 dana, što je dovelo do regresije smetnji vida na lijevom oku. Nakon akutnog liječenja simptoma postavlja 
se pitanje konačne dijagnoze i dugoročnog liječenja. Uzimajući u obzir prisutnost bubrežne insufi cijencije, eklampsiju u 
trudnoći uz spontani pobačaj, pozitivne rezultate genetskog testiranja i biokemijskih analiza za Fabryjevu bolest te nalaza 
MR mozga koji opisuje promjene dominantno u području stražnje cirkulacije zaključili smo da se u bolesnice najvjerojatnije 
radi o Fabryjevoj bolesti uz autoimune promjene u SŽS-u i da je bolesnicu potrebno liječiti enzimskom nadomjesnom tera-
pijom. S obzirom na smetnje vida i nalaze pozitivnih oligoklonskih vrpci koji mogu govoriti i u prilog multiple skleroze 
potrebno je dalje pratiti bolesnicu klinički i neuroradiološki kako bi se postavila konačna dijagnoza.
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